- Location
Janssen Biotech
"-
Johnson & Johnson's Janssen Biotech Inc. is Showing Interest in Stem Cell Therapy
Jan 9, 2014Johnson & Johnson's Janssen Biotech Inc. is showing interest in stem cell therapy delivered to the heart via a catheter. Janssen is providing an upfront payment of $12.5 million related to Capricor Therapeutics Inc.'s CAP-1002 therapy ...
Tags: Janssen, Catheter, Stem Cell Tech
-
JNJ and PCYC Have Won Approval From FDA for Their Breakthrough Therapy Imbruvica
Nov 15, 2013Johnson & Johnson (JNJ) subsidiary Janssen Biotech and Pharmacyclics (PCYC) have won approval from the US Food and Drug Administration (FDA) for their breakthrough therapy Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma ...
Tags: Johnson&Johnson, MCL Patients
-
NDA for The Investigational Oral BTK Inhibitor,Ibrutinib,Has Been Accepted by The US FDA
Sep 2, 2013Clinical-stage biopharmaceutical company Pharmacyclics' new drug application (NDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been accepted by the US FDA for two B-cell malignancy indications. ...
Tags: Solvay Group, Medicine
-
The US FDA Has Approved Golimumab for Infusion
Jul 19, 2013The US FDA has approved Janssen Biotech's Simponi ARIA (golimumab) for infusion to treat moderately to severely active rheumatoid arthritis (RA). Simponi ARIA is the only fully-human anti-tumor necrosis factor (TNF)-alpha infusible ...
-
Second Genome Has Signed a Microbiome Drug Discovery Deal with Janssen Biotech
Jun 8, 2013Second Genome has signed a microbiome drug discovery deal with Janssen Biotech to advance novel drug targets mediated by the bacterial ecosystem living within the human gut to treat ulcerative colitis. Under the collaboration, Janssen ...
Tags: Microbiome Drug, Medicine
-
Janssen Biotech Has Announced The FDA Approval of Simponi (Golimumab) to Treat Moderately
May 17, 2013Janssen Biotech has announced the FDA approval of Simponi (golimumab) to treat moderately to severely active ulcerative colitis (UC) in adult patients with corticosteroid dependence or an inadequate response to or failed to tolerate oral ...
Tags: FDA, Janssen Biotech
-
Genmab Has Obtained FDA Fast Track Designation in Double Refractory Multiple Myeloma
Apr 4, 2013Biotechnology company Genmab has obtained FDA fast track designation in double refractory multiple myeloma for daratumumab. As per the designation, the human CD38 monoclonal antibody Daratumumab is suitable for multiple myeloma patients ...
-
Abbott Has Entered Into a Collaboration Agreement
Feb 25, 2013Abbott has entered into a collaboration agreement with Janssen Biotech and Pharmacyclics to develop a molecular companion diagnostic test for investigational leukemia therapy. Under the agreement, Abbott will leverage its proprietary ...
Tags: leukemia therapy, Abbott, Pharmacyclics
-
West Has Entered Into a Agreement with Janssen to Develop New Self-Injection Technology
Dec 18, 2012West, a manufacturer of injectable drug delivery systems, has entered into a collaboration agreement with Janssen Biotech to develop new self-injection technology, designed to deliver pharmaceutical and biologic drug products. Under ...
Tags: company cooperation, self-injection technology, medical product
-
mCRPC Has Won FDA Approval for Use in Patients Who Have Not Received Chemotherapy
Dec 11, 2012Janssen's Zytiga indicated for metastatic castration-resistant prostate cancer(mCRPC),has won FDA approval for use in patients who have not received chemotherapy. The oral,once-daily medication was previously used in combination with ...
-
Janssen Biotech and Janssen Biologics Are Seeking Approval for Stelara in The US
Dec 10, 2012Janssen Biotech and Janssen Biologics are seeking approval for Stelara in the US and Europe for the treatment of active psoriatic arthritis. A supplemental biologics license application (sBLA) was submitted to the FDA and a Type II ...
-
The Drug Is Used to Treat Adult Patients with Moderately to Severely Active UC
Dec 5, 2012Janssen Biotech and Janssen Biologics have submitted a supplemental biologics license application (sBLA) to the US Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMA) seeking approval of Simponi ...
Tags: Simponi, golimumab, active ulcerative colitis, anti-tumor necrosis factor
-
Janssen, Genmab Has Executed a License and Development Agreement
Nov 29, 2012Janssen Biotech, a Johnson & Johnson company, has executed a license and development agreement for an investigational anti-cancer agent, daratumumab (HuMax-CD38), with Genmab. Daratumumab is a human CD38 monoclonal antibody which is ...
Tags: Daratumumab License, license and development agreement, anti-cancer
-
Janssen Biotech Signed a License Agreement for The Worldwide Development
Nov 29, 2012Janssen Biotech has signed a license agreement with Astellas Pharma for the worldwide development and commercialization of ASP015K, except in Japan. Astellas will continue development and commercialization of ASP015K in Japan. ASP015K, ...
Tags: Janssen Biotech, Astellas Pharma, license agreement, ASP015K
-
West Pharmaceutical Services Announces Agreement with Janssen Biotech
Sep 6, 2012West Pharmaceutical Services has announced an agreement with Janssen Biotech, a biotechnology company to partner on the development and manufacturing of a new self-injection product developed by Janssen. The new injection technology, ...